Cargando…

Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study

INTRODUCTION: MVC-COV1901 is a protein subunit COVID-19 vaccine based on the stable prefusion spike protein S-2P adjuvanted with CpG 1018 and aluminum hydroxide. Interim results of a phase 2 clinical trial demonstrated favorable safety profile and immunogenicity and the vaccine has been authorized f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsieh, Szu-Min, Chang, Shan-Chwen, Cheng, Hao-Yuan, Shih, Shin-Ru, Lien, Chia En
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112257/ https://www.ncbi.nlm.nih.gov/pubmed/35579840 http://dx.doi.org/10.1007/s40121-022-00652-6

Ejemplares similares

Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
por: Waits, Alexander, et al.
Publicado: (2022)

A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV
por: Cheng, Shu-Hsing, et al.
Publicado: (2022)

Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC—COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study
por: Hsieh, Szu-Min, et al.
Publicado: (2021)

Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222
por: Cheng, Shu-Hsing, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study
por: Huang, Szu-Ting, et al.
Publicado: (2023)

Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial
por: Liu, Luke Tzu-Chi, et al.
Publicado: (2022)

Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial
por: Estephan, Lila, et al.
Publicado: (2023)

Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine
por: Lin, Yi-Jiun, et al.
Publicado: (2022)

An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
por: Estrada, Josue Antonio, et al.
Publicado: (2022)

Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants
por: Chiu, Chun-Hsiang, et al.
Publicado: (2022)

An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay
por: Torales, Julio, et al.
Publicado: (2023)

Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
por: Hsieh, Szu-Min, et al.
Publicado: (2021)

A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19
por: Chen, Chih-Jung, et al.
Publicado: (2022)

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination
por: Liu, Yuag-Meng, et al.
Publicado: (2022)

Dose-Related Aberrant Inhibition of Intracellular Perforin Expression by S1 Subunit of Spike Glycoprotein That Contains Receptor-Binding Domain from SARS-CoV-2
por: Huang, Chun-Fu, et al.
Publicado: (2021)

SARS-CoV-2 Omicron Variant Neutralization after Third Dose Vaccination in PLWH
por: Vergori, Alessandra, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
por: Lee, I-Jung, et al.
Publicado: (2022)

Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant
por: Campos, Guilherme R. F., et al.
Publicado: (2022)

ASP.NET MVC in action: with MvcContrib, NHibernate, and more
por: Palermo, Jeffrey, et al.
Publicado: (2010)

Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine
por: Tauzin, Alexandra, et al.
Publicado: (2023)

Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
por: Luczkowiak, Joanna, et al.
Publicado: (2022)

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
por: Zhu, Ka-Li, et al.
Publicado: (2023)

Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection
por: Lee, Wen Shi, et al.
Publicado: (2023)

Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
por: Chavda, Vivek P., et al.
Publicado: (2022)

Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

Life after the MVC
por: Tzovanakis, Harris
Publicado: (2017)

Pro PHP MVC
por: Pitt, Chris
Publicado: (2012)

Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders
por: Harrington, Patrick, et al.
Publicado: (2022)

SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses
por: Mandolesi, Marco, et al.
Publicado: (2021)

Plasma Neutralization of the SARS-CoV-2 Omicron Variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Neutralization and Stability of SARS-CoV-2 Omicron Variant
por: Zeng, Cong, et al.
Publicado: (2021)

Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen
por: Srivastava, Vikram, et al.
Publicado: (2021)

Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster
por: Peng, Pai, et al.
Publicado: (2022)

Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents
por: Leung, Daniel, et al.
Publicado: (2023)

Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults
por: Schmidt, Pete, et al.
Publicado: (2023)

Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant
por: Yu, Xiaoling, et al.
Publicado: (2022)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vdqifp6o5ckih7r65p32s5t614